Breo Ellipta 2015 U.S. PROMOTIONAL AUDIT REPORT

Published July 2016 • 25 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Breo Ellipta through personal promotion in 2015 and how does this compare to its peer set in the Asthma and Chronic Obstructive Pulmonary Disease markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does GSK’s depth of coverage vary within key specialties (e.g., Family Medicine, Internal Medicine, Pulmonology, and Allergy/Immunology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Breo Ellipta throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Breo Ellipta in 2015?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 145,300 paid interactions across 43,400 physicians made on behalf of Breo Ellipta were carefully examined to support our analysis. In addition, interaction data from 22 peer products (e.g. Advair Diskus, Aerospan, Anoro Ellipta, Arnuity Ellipta, Asmanex, Brovana, Combivent Respimat, Daliresp, Dulera, Flovent, Incruse Ellipta, Nucala, Perforomist, ProAir, Qvar, Spiriva Respimat, Stiolto Respimat, Striverdi Respimat, Symbicort, Tudorza, Ventolin HFA, and Xolair) was leveraged to provide benchmarking and market insights.